93 related articles for article (PubMed ID: 22284262)
21. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
[TBL] [Abstract][Full Text] [Related]
22. Dosage-response in the treatment of Gaucher disease by enzyme replacement therapy.
Beutler E
Blood Cells Mol Dis; 2000 Aug; 26(4):303-6. PubMed ID: 11042031
[No Abstract] [Full Text] [Related]
23. Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher disease.
Barton NW; Brady RO; Dambrosia JM; Doppelt SH; Hill SC; Holder CA; Mankin HJ; Murray GJ; Zirzow GC; Parker RI
J Pediatr; 1992 Feb; 120(2 Pt 1):277-80. PubMed ID: 1735829
[TBL] [Abstract][Full Text] [Related]
24. No price too high?
Garber AM
N Engl J Med; 1992 Dec; 327(23):1676-8. PubMed ID: 1435903
[No Abstract] [Full Text] [Related]
25. Enzyme replacement therapy in type 1 and type 3 Gaucher's disease.
Zimran A; Elstein D; Abrahamov A
Lancet; 1995 Feb; 345(8947):451-2. PubMed ID: 7853968
[No Abstract] [Full Text] [Related]
26. Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease.
Erikson A; Forsberg H; Nilsson M; Aström M; Månsson JE
Acta Paediatr; 2006 Mar; 95(3):312-7. PubMed ID: 16497642
[TBL] [Abstract][Full Text] [Related]
27. [Enzyme therapy of Gaucher's disease].
Beck M
Dtsch Med Wochenschr; 1993 Jun; 118(25):964-5. PubMed ID: 8519225
[No Abstract] [Full Text] [Related]
28. Short-term withdrawal from imiglucerase: what can we learn from it?
Hollak CE
Blood Cells Mol Dis; 2011 Jan; 46(1):105-6. PubMed ID: 20684887
[No Abstract] [Full Text] [Related]
29. Low-dose versus high-frequency regimens in Gaucher's disease.
Hollak CE; Goudsmit R; van Oers MH
Lancet; 1996 Feb; 347(8998):406-7. PubMed ID: 8598739
[No Abstract] [Full Text] [Related]
30. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
Elstein D; Altarescu G; Maayan H; Phillips M; Abrahamov A; Hadas-Halpern I; Tiomkin M; Zimran A
Blood Cells Mol Dis; 2012 Jan; 48(1):45-50. PubMed ID: 22047948
[TBL] [Abstract][Full Text] [Related]
31. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
Drelichman G; Ponce E; Basack N; Freigeiro D; Aversa L; Graciela E; Kohan R
J Pediatr; 2007 Aug; 151(2):197-201. PubMed ID: 17643778
[TBL] [Abstract][Full Text] [Related]
32. Low-dose versus high-frequency regimens in Gaucher's disease.
Maródi L
Lancet; 1995 Nov; 346(8987):1434. PubMed ID: 7475855
[No Abstract] [Full Text] [Related]
33. Successful desensitization to imiglucerase of an adult patient diagnosed with type I Gaucher disease.
Erdoğdu D; Gelincik A; Canbaz B; Colakoğlu B; Büyüköztürk S; Tanakol R
Int Arch Allergy Immunol; 2013; 160(2):215-7. PubMed ID: 23018845
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
Giraldo P; Irún P; Alfonso P; Dalmau J; Fernández-Galán MA; Figueredo A; Hernández-Rivas JM; Julia A; Luño E; Marín-Jimenez F; Martín-Nuñez G; Montserrat JL; de la Serna J; Vidaller A; Villalón L; Pocovi M
Blood Cells Mol Dis; 2011 Jan; 46(1):115-8. PubMed ID: 20934891
[TBL] [Abstract][Full Text] [Related]
35. Improvement of bone disease with increased dose of glucocerebrosidase in a Gaucher disease patient who had a bone lesion presenting during low-dose enzyme replacement therapy.
Ueda T; Fukunaga Y; Migita M; Watanabe A; Kaneko K; Morita T; Yamamoto M
Acta Paediatr Jpn; 1996 Jun; 38(3):260-4. PubMed ID: 8741318
[TBL] [Abstract][Full Text] [Related]
36. Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination.
Capablo JL; Franco R; de Cabezón AS; Alfonso P; Pocovi M; Giraldo P
Epilepsia; 2007 Jul; 48(7):1406-8. PubMed ID: 17433057
[TBL] [Abstract][Full Text] [Related]
37. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
Hsu CC; Chien YH; Lai MY; Hwu WL
J Formos Med Assoc; 2002 Sep; 101(9):627-31. PubMed ID: 12645190
[TBL] [Abstract][Full Text] [Related]
38. Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.
Serratrice C; Bengherbia M; Alessandrini M; Grosbois B; Camou F; Pers YM; Bismuth M; Marie I; Belmatoug N; Berger M;
Blood Cells Mol Dis; 2014; 53(1-2):94-6. PubMed ID: 24411065
[No Abstract] [Full Text] [Related]
39. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
[TBL] [Abstract][Full Text] [Related]
40. [Enzyme replacement therapy: a new treatment concept in Gaucher disease].
Beck M; Mengel E; Barone R
Wien Klin Wochenschr; 1997 Feb; 109(3):81-5. PubMed ID: 9139464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
